ChondroGene Limited has completed the acquisition of GeneNews Inc. The principal asset of GeneNews is proprietary technology, in which ChondroGene presently holds certain licensing rights, in osteoarthritis, rheumatoid arthritis and traumatic joint injury. This technology can be applied to pharmacogenomics and personalized medicine, and in the development of novel diagnostics and therapeutics across a range Read more about Chondrogene Acquires Genenews[…]
Meridian Bioscience, Inc., will begin production of recombinant Trypanosoma cruzi (Chagas’ disease) antigen under a license agreement with Corixa Corporation. Manufacture will take place in its life science production laboratories located at Viral Antigens, Inc., (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers Read more about Meridian Agrees License Deal With Corixa[…]
Ciphergen Biosystems, Inc. has announced that Toronto Medical Laboratories (TML) has acquired Ciphergen’s AutoBiomarker ProteinChip System, with an objective of pursuing targeted assay development projects aimed at identifying new protein biomarkers that can be converted into commercial diagnostic tests as part of the TML reference lab business strategy. Ciphergen has granted TML, in conjunction with Read more about Toronto Medical Has Acquired Ciphergen’s Autobiomarker Proteinchip System[…]
Diagnostic Products Corporation (DPC) has announced that MBL of Japan has granted DPC a license to develop and commercialize diagnostic antinuclear antibody (ANA) assays on its IMMULITE immunochemistry analyzers, and applications for the DPC ANA lineBlot assay. “The combination of IMMULITE automation and the ANA technology represents a significant step forward in autoimmune testing,” said Read more about Diagnostic Products Announces License Agreement With MBL[…]
Neoprobe Corporation has announced that it has completed an exclusive license agreement with the University of California, San Diego (UCSD). The license affords Neoprobe the rights to a proprietary compound developed by researchers at UCSD. The compound, which Neoprobe has designated Lymphoseek (TM), is being evaluated in clinical studies to determine its effectiveness in identifying Read more about Neoprobe Completes License For Lymphatic Agent[…]
AlleCure Corp. has announced a research collaboration with BD Biosciences (BDB), a division of BD (Becton, Dickinson and Company), to develop novel assays in support of AlleCure’s AlleVax treatments for allergies and various autoimmune diseases. Leveraging BD Biosciences research and clinical diagnostic systems and AlleCure’s allergy vaccine technologies, the collaboration will focus on the development Read more about Allecure, BD Biosciences Announce Collaborative Research Alliance[…]
Bayer Corporation, Diagnostics Division and Visible Genetics Inc. (VGI) have signed a definitive agreement providing for Bayer Diagnostics to acquire VGI in a cash deal valued at $61.4 million, significantly expanding Bayer’s position in the growing Nucleic Acid Diagnostic (NAD) segment of the Professional Laboratory market. Bayer will purchase, for cash consideration, VGI’s outstanding common Read more about Bayer Diagnostics To Acquire Visible Genetics[…]
diaDexus, Inc Mayo Clinic, and Mayo Medical Laboratories, the national reference laboratory for Mayo Clinic, have entered into a collaborative agreement to explore the clinical applications for a test that detects a newly identified independent risk factor for cardiovascular disease. The test, called the PLAC Test, was developed by diaDexus as a potential new way Read more about diaDexus Collaborates On Cardiovascular Diagnostic[…]
Transgenomic Inc. and non-profit organization PXE International have entered into a collaboration to develop a diagnostic test for the genetic condition, pseudoxanthoma elasticum, commonly known as PXE. The intent is to develop a test based on Transgenomic’s WAVE System and make it available to laboratories around the world. PXE, which affects an estimated one in Read more about Transgenomic Signs Collaboration Agreement With PXE[…]
Phase-1 Molecular Toxicology Inc. has announced a large collaborative research agreement with Boehringer Ingelheim Pharmaceuticals Inc. to develop diagnostic technologies to identify which patients will suffer from adverse reactions to drugs prior to treatment. Spencer Farr, Ph.D. CEO of Phase-1 had this to say about the collaboration with Boehringer Ingelheim Pharmaceuticals: “We believe that this Read more about Phase-1 Molecular Toxicology To Develop Diagnostic Technologies[…]